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The aim of this study was to investigate the prevalence of carbapenem-resistant
Klebsiella pneumoniae (CRKP) and the most common types of carbapenemases,
metallo-beta-lactamases (MBLs), and extended-spectrum beta-lactamases (ESBLs)
among CRKP isolates in a tertiary hospital in Isfahan, Iran. Eighty non-repetitive
clinical isolates of K. pneumoniae were obtained from different clinical specimens.
Antibiotic resistance pattern of isolates was determined by disk diffusion method and
production of carbapenemases and MBLs was conﬁrmed using modiﬁed Hodge test
and E-test, respectively. Molecular detection of the antibiotic resistance genes was
performed using PCR. Fifty-one (63.8%) isolates have decreased susceptibility to
carbapenems, of which 46 (90.2%) isolates were as carbapenemase producer and four
(7.8%) isolates were positive for MBLs, phenotypically. The results of PCR showed
that the prevalence of blaOXA-48, blaNDM, blaSHV, blaCTX-M, and blaTEM genes among
CRKP isolates were 90.2%, 15.7%, 98%, 96.1%, and 90.2%, respectively. No isolates
carrying the blaKPC, blaGES, blaIMI, blaVIM, and blaIMP genes were detected. This
study showed that the production of OXA-48 is one of the main mechanisms of
resistance to carbapenems in CRKP isolates in Isfahan. In addition, the dissemination
of NDM-producing CRKP isolates is a potential risk for the health care system of this
area in the near future.
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Introduction
Klebsiella pneumoniae is an important opportunistic bacterial pathogen
associated with both community- and hospital-acquired infections and potentially
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causing mortality, especially in hospitalized patients [1]. An important part of
hospital infections (4%–8%) is due to this bacterium. K. pneumoniae isolates are
increasingly resistant to several antibiotics. Hospital outbreaks caused by
K. pneumoniae isolates are frequent and the transmission of resistant strains
between the hospital and community has been described previously [2]. Treatment
of infections caused by drug-resistant K. pneumoniae isolates, especially strains
producing extended-spectrum beta-lactamases (ESBLs), as well as isolates with
multidrug-resistant and extensively drug-resistant phenotypes is very complicated
and costly, and usually not associated with satisfactory results [3, 4]. Carbapenems
are a group of beta-lactam antibiotics that have been used as the “last-line”
treatment for Enterobacteriaceae-associated infections, especially those produc-
ing ESBLs [5, 6]. Compared to cephalosporins, penicillins, or beta-lactam/
beta-lactamase inhibitors, carbapenems have a broader antimicrobial spectrum
[7]. During the past decade, the emergence of resistance to carbapenems in glucose
non-fermenting (e.g., Pseudomonas aeruginosa and Acinetobacter baumannii)
and glucose-fermenting (e.g., Enterobacteriaceae) Gram-negative bacilli has been
reported from all around the world [8, 9]. Recently, the spread of carbapenem-
resistant Enterobacteriaceae, especially carbapenem-resistant K. pneumoniae
(CRKP), is the most important clinical problem in the ﬁeld of antibiotic resistance
that should be monitored seriously and prevented from its progress [10]. This
study aims to investigate the prevalence of CRKP and the most common types of
carbapenemases, metallo-beta-lactamases (MBLs), and ESBLs among CRKP in a
tertiary hospital in Isfahan, Iran.
Materials and Methods
Bacterial isolates
During a 9-month period, April–December 2017, 80 non-repetitive
K. pneumoniae isolates were obtained from various specimens of inpatients in
Alzahra hospital, Isfahan, Iran. All isolates were identiﬁed in microbiology
laboratory of medical school using the conventional methods, such as Gram
staining and biochemical (oxidase, sugar fermentation, IMViC, Kliger’s iron agar,
nitrate reduction, motility, etc.) tests [11]. In addition, to conﬁrm the species, a
PCR detection based on the 16S–23S internal transcribed spacer sequence of
K. pneumoniae was conducted [12]. This study was evaluated and approved
by the Ethics Committee of Isfahan University of Medical Sciences (project
no. 395891).
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Antibiotic susceptibility testing
Susceptibility to antibiotics was determined using Kirby–Bauer’s disk
diffusion method according to the recommendations of Clinical Laboratory
Standard Institute (CLSI) [13]. For this purpose, 18 antibiotics (MAST, UK and
Lioﬁlchem, Italy) including imipenem (10 μg), meropenem (10 μg), ertapenem
(10 μg), gentamicin (10 μg), ceftaroline (30 μg), piperacillin/tazobactam
(100/10 μg), cefazolin (30 μg), cefuroxime (30 μg), ceftazidime (30 μg), cefepime
(30 μg), cefoxitin (30 μg), ciproﬂoxacin (5 μg), trimethoprim/sulfamethoxazole
(1.25/23.75 μg), tigecycline (15 μg), aztreonam (30 μg), amoxicillin/clavulanic
acid (20/10 μg), chloramphenicol (30 μg), and tetracycline (30 μg) were used.
Escherichia coli ATCC 25922 was used for quality control of disk diffusion
method [13].
Carbapenemase and MBL screening assays
To determine carbapenemase activity, the modiﬁed Hodge test (MHT) using
ertapenem disk (MAST) was performed according to CLSI guidelines [13].
Moreover, to detect MBL activity, E-test method using strips containing
meropenem/meropenem + EDTA (Lioﬁlchem) was carried out based on manu-
facturer’s guidelines.
PCR for detection of antibiotic resistance genes
DNA was extracted using the boiling method and used as template for PCR
[14]. To detect antibiotic resistance genes including blaKPC, blaGES, blaIMI,
blaVIM, blaIMP, blaNDM, blaOXA-48, blaSHV, blaTEM, and blaCTX-M, separate PCR
reactions were performed. The list of all target genes and corresponding primers is
presented in Table I [15–21]. PCR was performed using commercially available
PCR Master Mix (AMPLIQON, Denmark) according to the manufacturer’s
instructions. Brieﬂy, 1 μl template DNA (∼100 ng/μl), 1 μl of each primer
(10 pmoles/μl), and 9.5 μl DNase-free distilled water were added to 12.5 μl of
Master Mix in a ﬁnal volume of 25 μl. Thermocycling was carried out with an
initial denaturation step at 95 °C for 5 min, followed by 35 cycles of denaturation
at 95 °C for 30 s, annealing for 45 s at primer-speciﬁc temperatures (Table I),
extension at 72 °C for 1 min, and a ﬁnal extension step at 72 °C for 10 min. PCR
products were resolved by standard electrophoresis on 1.5% agarose gel contain-
ing DNA safe stain.
CHARACTERIZATION OF CRKP CLINICAL ISOLATES 337
Acta Microbiologica et Immunologica Hungarica 65, 2018
Results
Bacterial isolates
Table II shows demographic information and clinical characteristics of
patients infected with K. pneumoniae. The mean age of patients was 52.7 years.
Antibiotic susceptibility testing
Table III shows the results of antibiotic susceptibility testing in considered
isolates. The highest resistance rate was observed to cefazolin (87.5%), followed
by amoxicillin/clavulanic acid (78.8%), cefuroxime (77.5%), tetracycline (77.5%),
and aztreonam (76.2%). Tigecycline and chloramphenicol were the most effective
antibiotics with 13.7% and 18.7% resistance rate, respectively. About 62.5% of
isolates were resistant to meropenem and ertapenem as well as overall, 51 isolates
showed the decreased susceptibility to carbapenems.
Table I. List of primers, expected amplicon size, and annealing temperatures
Target






blaKPC F: GATACCACGTTCCGTCTGG 58 246 [15]
R: GCAGGTTCCGGTTTTGTCTC
blaGES F: GTTTTGCAATGTGCTCAACG 53 371 [16]
R: TGCCATAGCAATAGGCGTAG
blaIMI F: ATGTCATTAGGTGATATGGC 50 879 [17]
R: GCATAATCATTTGCCGTACC
blaVIM F: TTTGGTCGCATATCGCAACG 66 500 [18]
R: CCATTCAGCCAGATCGGCAT
blaIMP F: GTTTATGTTCATACATCG 45 440 [18]
R: GGTTTAACAAAACAACCAC
blaNDM F: GGGCAGTCGCTTCCAACGGT 52 475 [19]
R: GTAGTGCTCAGTGTCGGCAT
blaOXA-48 F: GCGTGGTTAAGGATGAACAC 60 438 [20]
R: CATCAAGTTCAACCCAACCG
blaSHV F: ATGCGTTATATTCGCCTGTG 60 753 [18]
R: TGCTTTGTTATTCGGGCCAA
blaTEM F: AAACGCTGGTGAAAGTA 45 752 [18]
R: AGCGATCTGTCTAT
blaCTX-M F: TTTGCGATGTGCAGTACCAGTAA 51 544 [21]
R: CGATATCGTTGGTGGTGCCATA
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Table II. Demographic information and clinical characteristics of patients
infected with K. pneumoniae (n= 80)
Demographics Number (%)





Intensive care unit 48 (60.0)
Internal medicine 12 (15.0)
Surgery 8 (10.0)
Emergency 7 (8.8)











Bronchoalveolar lavage 1 (1.2)
Drainage ﬂuid 1 (1.2)
Table III. Antibiotic susceptibility of K. pneumoniae isolates (n= 80)
Antibiotic Susceptible [n (%)] Intermediate [n (%)] Resistant [n (%)]
Imipenem 31 (38.8) 3 (3.7) 46 (57.5)
Meropenem 30 (37.5) 0 (0.0) 50 (62.5)
Ertapenem 30 (37.5) 0 (0.0) 50 (62.5)
Gentamicin 31 (38.8) 1 (1.2) 48 (60.0)
Ceftaroline 20 (25.0) 1 (1.2) 59 (73.8)
Piperacillin/tazobactam 24 (30.0) 4 (5.0) 52 (65.0)
Cefazolin 7 (8.8) 3 (3.7) 70 (87.5)
Cefuroxime 16 (20.0) 2 (2.5) 62 (77.5)
Ceftazidime 17 (21.3) 3 (3.7) 60 (75.0)
Cefepime 17 (21.3) 4 (5.0) 59 (73.7)
Cefoxitin 24 (30.0) 2 (2.5) 54 (67.5)
Ciproﬂoxacin 19 (23.8) 1 (1.2) 60 (75.0)
Trimethoprim/sulfamethoxazole 37 (46.3) 1 (1.2) 42 (52.5)
Tigecycline 57 (71.3) 12 (15.0) 11 (13.7)
Aztreonam 17 (21.3) 2 (2.5) 61 (76.2)
Amoxicillin/clavulanic acid 13 (16.2) 4 (5.0) 63 (78.8)
Chloramphenicol 36 (45.0) 29 (36.3) 15 (18.7)
Tetracycline 17 (21.3) 1 (1.2) 62 (77.5)
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Carbapenemase and MBL screening assays
The MHT was performed on 51 isolates with decreased susceptibility to
carbapenems and following results were obtained: 46 (90.2%) isolates were
positive, 4 (7.8%) isolates were negative, and 1 (2%) isolate was indeterminate.
Similarly, phenotypic MBL production testing on desired isolates identiﬁed 4
(7.8%) isolates as positive, 4 (7.8%) isolates as negative, and 43 (84.4%) isolates
with non-determinable results.
PCR for detection of antibiotic resistance genes
All 51 isolates with decreased susceptibility to carbapenems were tested in
PCR for the presence of the selected antibiotic resistance genes. Forty-six (90.2%)
isolates harbored blaOXA-48 and eight (15.7%) isolates were positive for blaNDM.
Moreover, seven (13.7%) isolates had both blaOXA-48 and blaNDM, simultaneous-
ly. ESBLs-encoding genes including blaSHV, blaCTX-M, and blaTEM were identi-
ﬁed in 98%, 96.1%, and 90.2% isolates, respectively. Similarly, these (ESBLs)
genes were detected concurrently in 45 (88.2%) isolates. In addition, six (11.8%)
isolates were positive for the presence of blaOXA-48, blaNDM, blaSHV, blaCTX-M,
and blaTEM genes, together. The results of PCR were negative for blaKPC, blaGES,
blaIMI, blaVIM, and blaIMP genes.
Discussion
One of the main problems in dealing with clinical strains of K. pneumoniae
is the increasing incidence of resistance to antibiotics. These resistant strains are
rapidly expanding and have caused many problems with the treatment of infec-
tions in various health care settings [22]. Carbapenems are a group of beta-lactam
antibiotics that are used to treat serious infections in hospitals. The constant uses of
these antibiotics and the selective pressure resulting from it have led to resistance
to these antibiotics in Gram-negative bacteria, especially K. pneumoniae [5].
Usually, infections caused by CRKP threaten patients in hospitals, nursing homes,
and other health care centers and do not occur in immunocompetent persons
[23, 24]. In this study, more than half of patients were over 56.5 years of age. In
addition, almost half of CRKP isolates (45%) were obtained from hospitalized
patients in intensive care unit, which highlights the importance of aging and
long-term hospitalization in these infections. PCR results showed that 90.2% of
CRKP isolates were positive for blaOXA-48. OXA-48-producing Enterobacteriaceae
was ﬁrst identiﬁed in Turkey in 2001, subsequently reported from several countries
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in the Middle East, North Africa, and Europe [25, 26]. The ﬁrst report of OXA-48-
producing K. pneumoniae strains in Iran was presented by Azimi et al. [27]. In two
separate studies conducted in Tehran hospitals (capital of Iran), the prevalence of
blaOXA-48 among CRKP isolates was reported as 96.4% [27] and 4.1% [28].
Another study in southwestern Iran showed that 6.9% of CRKP isolates were
positive for blaOXA-48 [29]. The results of this study regarding the prevalence of
blaOXA-48-harboring CRKP is in parallel with the study by Solgi et al. [30]
between 2014 and 2016 in our region. In their study, all (100%) CRKP isolates
harbored blaOXA-48. The results of the phenotypic test for detection of MBLs
showed that only four (7.8%) CRKP isolates produced MBLs, while in the PCR
assay, eight (15.7%) CRKP isolates were identiﬁed as blaNDM-positive. This
ﬁnding suggests that the phenotypic test alone is not sufﬁcient for the deﬁnitive
detection of MBLs, and a molecular test such as PCR should be used along with it.
ESBLs-encoding genes including blaSHV, blaCTX-M, and blaTEM with 98%,
96.1%, and 90.2% were the most prevalent bla genes among CRKP isolates,
respectively. In a meta-analysis article that we previously published in Iran, the
overall relative frequency (RF) of blaCTX-M gene among ESBLs-producing
K. pneumoniae clinical isolates was 56.7% [31]. Our results show that the RF
of blaCTX-M among CRKP isolates in Isfahan is higher than its RF in Iran. Solgi
et al. [30] in their study from Isfahan have reported that 95.8%, 94.8%, and 96.9%
of CRKP isolates were positive for blaCTX-M, blaTEM, and blaSHV, respectively. In
this case, our results were fully consistent with their results. Similar to other
studies that were carried out previously in Isfahan, we have not detected class A
carbapenemases (KPC, GES, and IMI) among CRKP isolates [30, 32, 33]. In
conclusion, this study showed that the production of class D carbapenemases
(OXA-48) is one of the main mechanisms of resistance to carbapenems in CRKP
isolates in Isfahan. Moreover, the dissemination of NDM-producing CRKP
isolates is a potential hazard for the health care system of this area in the future
that should be controlled.
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